ABLYNX WINS EUROPEAN MEDISCIENCE AWARD FOR THE SECOND YEAR IN A ROW
(Thomson Reuters ONE) -
GHENT, Belgium, 28 June, 2010 - Ablynx [Euronext Brussels: ABLX] has won the
award for 'Best Technology' at the 2010 European Mediscience Awards for the
second time in two years.
The European Mediscience Awards Dinner, sponsored by Piper Jaffray, is the
largest annual gathering of quoted biotech and life sciences companies in
Europe. It celebrates the best in the sector and highlights the achievements of
individuals and companies. The event recognises the importance of access to the
capital markets to fund growth and innovation and is attended by specialist
investors, advisors, media and analysts.
Best Technology Award - Ablynx's Nanobodies(®)
Nanobodies are a new class of novel therapeutic proteins that are derived from
naturally occurring single-chain antibodies. The basis for Nanobody technology
was originally discovered in 1992 at the Free University of Brussels. The
invention was based on the observation that Camelidae (the family which includes
camels and llamas) are the only mammals which, in addition to conventional
antibodies, also possess antibodies that lack light chains but still have the
full antigen-binding capacity of conventional antibodies. In these heavy-chain
only antibodies, antigen binding occurs through a single variable domain
(V(HH)), which is the smallest functional antibody fragment of a naturally
occurring heavy-chain antibody and from which Nanobodies are derived.
On behalf of the voting panel, Kate Silverton said: "As befits the European
Mediscience Awards, the shortlist of technologies are novel, exciting and have
tremendous potential. Having won this award last year as well, Ablynx's
Nanobody technology platform is undoubtedly best in class and it is a great
achievement to win this award two years in a row."
Dr Moses, Chief Executive Officer and Chairman of Ablynx, commented: "We are
delighted to have won this prestigious award against such strong competition.
Since Ablynx was founded in 2001, we have invested in building a robust and well
validated technology platform which has, over the last four years, yielded a
very strong portfolio of over 25 Nanobody-based therapeutic programmes with four
Nanobody-based products now in the clinic."
For more information, please contact Ablynx:
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: eva-lotta.allan(at)ablynx.com
[HUG#1427867]
Complete version of the press release: http://hugin.info/137912/R/1427867/375446.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Ablynx via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 28.06.2010 - 18:07 Uhr
Sprache: Deutsch
News-ID 23133
Anzahl Zeichen: 0
contact information:
Town:
Ghent
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 298 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX WINS EUROPEAN MEDISCIENCE AWARD FOR THE SECOND YEAR IN A ROW"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
